4 terminated, 3 completed, 1 withdrawn. 8 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 4, Completed 3, Withdrawn 1 |
| Phase 1 | 6 | Terminated 4, Completed 2 |
Follow Altor BioScience: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) Elotuzumab, Melphalan, Autologous Stem Cell Transplant (ASCT) - Multiple Myeloma | Phase 2 | Withdrawn | University of Arkansas | 2019-11-01 | 2020-07-10 | |
| ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer ALT-803, Nivolumab - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Medical University of South Carolina | 67 | 2016-01-08 | 2026-02-17 |
| QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab Rituximab, N-803 - Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Altor BioScience | 43 | 2015-04-17 | 2024-07-03 |
| QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma ALT-801 - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Altor BioScience | 6 | 2012-08-14 | 2024-06-18 |
| A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer ALT-801, Gemcitabine - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Terminated | Altor BioScience | 12 | 2012-03-30 | 2024-07-19 |
| A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Cisplatin, Gemcitabine, ALT-801 - Transitional Cell Carcinoma of Bladder, Urethra Cancer | Phase 1 / Phase 2 | Completed | Altor BioScience | 68 | 2011-09-06 | 2024-06-25 |
| QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma Cisplatin, ALT-801 - Metastatic Melanoma | Phase 1 / Phase 2 | Terminated | Altor BioScience | 22 | 2010-02-01 | 2026-09-10 |
| Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome ALT-836, Placebo - Sepsis, Acute Lung Injury | Phase 2 | Completed | Altor BioScience | 150 | 2009-04-01 | 2015-04-10 |
Neoplasms (5) · Neoplasm Metastasis (3) · Recurrence (3) · Multiple Myeloma (2) · Urinary Bladder Neoplasms (2) · Acute Lung Injury (1) · Carcinoma in Situ (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1)
ALT-801 (4) · ALT-803 (3) · Cisplatin (2) · Gemcitabine (2) · ALT-836 (1) · Cell Count (1) · Melphalan (1) · Nivolumab (1) · Rituximab (1) · elotuzumab (1)
United States (8)
Frits van Rhee, MD, PhD (1) · Hing C Wong, PhD (1) · Hing Wong, PhD (1) · John Wrangle, MD (1)
PMID 22340260, PMID 29628312, PMID 33832946
R44CA097550 (1)